GNRHR and prostate cancer: In line with these observations, Gnanapragasam and coworkers [14] have reported that in patients with established progression to hormone refractory disease, GnRH agonist-based therapy, in the presence of high prostate cancer GnRH receptor expression, is associated with improved disease-specific survival.